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Global regulatory developments for clinical stem cell research: diversification 
and challenges to collaborations 
 
Abstract 
 
In this article we explore regulatory developments in stem cell medicine in seven 
jurisdictions: Japan, China, India, Argentina, Brazil, the USA and the European 
Union. We will show that the research methods, ethical standards and approval 
procedures for the market use of clinical stem cell interventions are undergoing an 
important process of global diversification. We will discuss the implications of this 
process for international harmonization and the conduct of multicountry clinical 
research collaborations. It will become clear that the increasing heterogeneity of 
research standards and regulations in the stem cell field presents a significant 
challenge to international clinical trial partnerships, especially with countries that 
diverge from the regulatory models that have been developed in the USA and the 
European Union.  
 
Keywords: Clinical Stem Cell Research, Research Regulation, Evidence-based 
Medicine, Multi-Country Trials, International Harmonization 
 
Introduction 
 
The regulatory conditions through which stem cell treatments are translated from the 
lab bench to the clinic and the market are currently in the midst of a renegotiation 
process [1], [2], [3]. A key problem for the stem cell field is that existing regulatory 
approaches for the clinical testing and market approval of new drugs do not neatly 
map onto stem cell interventions. The biological characteristics of stem cells and 
specific risks for patients require new and tailor-made regulatory frameworks to 
reliably address scientific and health risks [4]. But the development of regulatory 
frameworks for stem cell medicine has also been complicated by the widespread 
availability of unproven or non-systematically tested for-profit interventions with 
stem cells in many countries [5]. Lucrative business opportunities and widespread 
demands of patients have resulted in calls for increased access to experimental stem 
cell interventions and the development of regulatory alternatives. Disagreements have 
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arisen in particular with regard to the acceptability of experimental stem cell 
interventions outside of the methodological format of the multiphase randomized 
controlled trial (RCT), and also the provision of experimental therapies independent 
from the review of drug regulatory authorities.  
The position of the International Society for Stem Cell Research (ISSCR), as 
published in its recent Guidelines for Stem Cell Research and Clinical Translation, is 
that stem ‘cell based medical products should rarely if ever be developed outside of a 
formal clinical trials process’ [6]. The ISSCR acknowledges, though, ‘that in some 
very limited cases, clinicians may be justified in attempting medically innovative 
stem cell-based interventions in a small number of seriously ill patients’. However, 
providers of experimental stem cell interventions should ‘under no circumstances’ be 
allowed to ‘promote, advertise, attempt general recruitment of patients, or 
commercialize such interventions’ [6].  
On the other hand, guidelines from other international societies, such as the 
International Cellular Medicine Society [7] or the International Association of 
Neurorestoratology [8] have argued in favour of clinical applications outside of the 
multiphase clinical trial system [3]. In practice, the provision of commercial clinical 
stem cell interventions that are offered to patients without systematic clinical research 
continues to occur on a large scale. McMahon has, in this respect, spoken of the rise 
of a “global industry” of unproven or non-systematically tested stem cell interventions 
[5]. She has estimated that in the last fifteen years or so several hundred thousands of 
patients have received experimental stem cell interventions.  
In Part I of this article we will explore how regulatory authorities in the above-
mentioned jurisdictions have reacted to these developments. The questions we ask 
are: what are current developments and trends in the regulation of clinical stem cell 
interventions and in which ways do these developments challenge the dominant 
paradigm of evidence-based medicine (EBM) and multi-phase controlled trials in 
clinical stem cell research. We will show that, even though the clinical evaluation and 
market approval of stem cell interventions through EBM standards and the use of the 
multiphase RCT system are still important in many countries, a continuing process of 
regulatory diversification is underway. Moreover, regulatory arrangements are still 
evolving in many societies, which has given rise to uncertainties, and which has made 
efforts of international harmonization more difficult. As we will show, the shift 
toward regulatory diversification is characterized by three central processes: first, an 
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increasing number of regulatory exceptions and exemptions, that allows for clinical 
applications with stem cells outside of the multiphase trial system; second, lenient 
enforcement of regulatory rules in many countries, which have resulted in the 
widespread toleration of experimental for-profit practices despite the fact that official 
regulatory protocols impose the mandatory use of RCTs; third, the emerging of 
entirely new regulatory models. This is most clearly exemplified by the case of Japan, 
which in 2014 introduced a model of conditional market approval for stem cell 
products that allows sidelining the phase I-III clinical trial system. 
In Part II we will explore the implications of these processes for international 
harmonization and the conduct of international clinical research collaborations. We 
will show that the absence of internationally binding standards for clinical stem cell 
research presents a huge challenge to multicountry clinical trial partnerships. Four 
types of challenges will be highlighted and illustrated through a case study of the 
China Spinal Cord Injury Network (China SCI Net), which has been the first 
intercontinental clinical trials infrastructure in the stem cell field between the USA 
and East Asia.  
 
Regulatory comparison 
 
United States of America 
 
The USA was the first country to have issued a formal regulation for clinical use and 
market approval of stem cell interventions. FDA rules went into effect with the 
interim rule Human Cells, Tissues, and Cellular and Tissue-Based Products: Donor 
Screening and Testing, and Related Labeling, which was issued on May 25, 2005 [9]. 
On June 19 2007 this interim rule was adopted as a final rule, without change, and 
released as the US FDA’s Regulation For Human, Cellular and Tissue Products 
(HCT/Ps). [10]. This regulatory framework introduced a risk-based, tiered approach 
that regulates stem cells as biological products within two categories: “351 products” 
and “361 products” [10]. The “351” category refers to cells that are more than 
minimally manipulated and to cells that are used in a non-homologous manner. These 
cells are classified as a biological drug product and they are subject to US Food and 
Drug Administration (FDA) pre-market approval. 351 biological products must ‘by 
law […] go through the multi-phase drug pipeline approval process starting after pre- 
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clinical studies with an Investigational New Drug (IND) application and proceeding 
to Phase 1 trials’ and then to Phase II and III trials [11].  
In a recent effort to create more flexible pathways to market approval of new 
drugs and biological products, the FDA has introduced since 2012 three types of 
regulatory exceptions, which can also be granted to human cell and tissue products 
[11]. These exceptions aim at: (i) speeding up the transition from preclinical to 
clinical testing (“fast track approval”) [12], (ii) accelerated authorization of phase I 
and II clinical trials that involve seriously ill patients with low life expectancy 
(“accelerated approval”) [13], and (iii) more rapid clinical testing of ‘breakthrough 
therapies’ that have the potential to treat a serious or potentially life threatening 
disease (“breakthrough therapy designation”) [14]. In addition to these more recent 
regulatory exceptions, the FDA offers also a “priority review” procedure, which was 
introduced in 1992. Priority review aims to expedite the duration of the evaluation 
process that precedes market approval of a new drug (six instead of ten months), after 
the completion of the clinical trial period [15]. A fifth regulatory exception is the 
“expanded access” program (also called “compassionate use program”). This program 
provides patients access to investigational new treatments parallel to (but outside of) 
FDA-approved phase II and III clinical trials [16]. The expanded use program dates 
back to 1987, but was revised in 2009 to ensure ‘broad and equitable access to 
investigational drugs for treatment’, including access to biological drug products [17]. 
The “361” category regulates the use of minimally manipulated stem cells that 
are applied for homologous use. These cells are not subject to pre-market approval by 
the FDA and they can be used in patients under compliance with the US human tissue 
regulation [18]. A large direct-to-consumer market with ‘361’ stem cell products has 
emerged in the USA in recent years [11]. While many of these clinics purport to offer 
self-classified ‘361’ products, there have been reports that several of these 
interventions were actually unproven ‘351’ products which were offered to patients 
illegally [11]. In response to these claims, the FDA published in November 2015 a 
draft guidance for a revised and more stringent regulatory approach, which was 
designed to address this problem [19] [20]. At the time of writing this article, though, 
this draft guidance was not yet finalized.    
 
 
European Union  
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Regulatory arrangements for stem cell treatments in the EU are similar to the US 
model. Cells that are more than minimally manipulated and used in non-homologous 
contexts are defined as “medicinal products” and are regulated under the Advanced 
Therapy Medicinal Products (ATMP) legislation, which was issued by the European 
Medicines Agency (EMA) in November 2007. Minimally manipulated autologous 
stem cells, on the other hand, are regulated under the human tissue legislations of 
European member states, and not centrally under EMA [21]. The ATMP regulation 
has harmonized regulatory approaches for clinical stem cell research in EU member 
states, to enable clinical collaborations and cross-country approval of stem cell 
products outside of the EU. As in the USA, the EMA regulation demands evidence 
from systematic clinical studies, typically from multiphase trials. In contrast to the 
USA, the EU has not experienced the emerging of a large-scale consumer market with 
minimally manipulated stem cells [22]. However, demands of patients to widen 
access to stem cell interventions have been addressed through a range of regulatory 
exceptions and exemptions. As in the USA, the EMA has introduced a 
“compassionate use” program, which allows access to new drugs and biological 
products (including stem cell products) outside of premarket clinical trials [23]. 
Unlike in the USA, however, EMA has also introduced a so-called “hospital 
exemption” program for stem cell interventions. This program allows the provision of 
cellular medicinal products to individual patients “in a European hospital under the 
exclusive professional responsibility of a doctor” [22]. These hospital exemptions are 
authorized for use by the regulatory authority in the country in which the product is 
applied. As a result, the hospital exemption scheme has been implemented unevenly 
across EU member states [1]. In some countries, the scheme has been used to approve 
large numbers of experimental interventions and has created “the opportunity for a 
legal market of authorised stem cell therapy products to emerge within the province of 
the clinical professionalism” [24]. More recently, EMA has also introduced a 
“conditional market approval” scheme [25], which can be used also for stem cell 
interventions. According to this scheme, a stem cell product can be licensed at a later 
stage of a phase III trial, when data collection for efficacy and safety has almost been 
completed. 
 
Japan 
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Pre-market evaluation of stem cell therapies in Japan was initially based on a similar 
regulatory model as in the USA and the EU. Until 2014 stem cell interventions were 
regulated under the Pharmaceutical Affairs Law (PAL) and treated either as 
pharmaceutical drug products, medical devices or combination products [26]. This 
regulatory pathway involved systematic multi-phase trials and compliance with good 
clinical practice (GCP) standards [26]. Then in May 2013 the Japanese National Diet 
passed the Regenerative Medicine Promotion Act [RMPA] [27], which formed the 
starting point of a radical regulatory reform. The RMPA was followed by the passing 
of the Amended Pharmaceutical Affairs Law, which went into effect in November 
2014 [28]. Under the amended PAL the conditions for the clinical application of stem 
cell interventions changed significantly [26]. The amended law allowed for 
conditional, limited-term market approval of stem cell products after early-phase 
clinical trials. Conditional approval can occur after positive clinical data from as few 
as ten patients [29], provided these first-in-human-trials demonstrate that the tested 
cell products are safe and “likely to predict efficacy” [30]. Once approved by the 
Japanese Pharmaceuticals and Medical Devices Agency (PMDA), clinical trial 
sponsors have the possibility to seek market approval for up to seven years [30]. 
Clinical efficacy is tested in this time period in post-marketing procedures [31]. This 
is a significant shift away from the multiphase RCT system, which has emerged as the 
methodological gold standard in medicine research in the recent decades. This break, 
and the possibility to time-limited conditional market approval after evidence from 
small numbers of patients, is likely to have repercussions for the regulation of stem 
cell research in other countries, and possibly also other fields of medicine research. 
It is also noteworthy that conditionally approved stem cell interventions are 
eligible for reimbursement by the Japanese health insurance system [26]. Costs for 
these experimental treatments are split between the state and patients at a ratio of 
70:30 [30]. This is a drastic change to the financing of research and development 
(R&D) costs for medicine research, which typically requires long-standing corporate 
or government investments before development costs could be amortized through 
health insurance reimbursement and consumer charges.  
 
India 
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The governance of the clinical stem cell field in India started with the introduction of 
the Guidelines for Stem Cell Research and Therapy [32] a regulatory guidance 
document that was joint-issued by the Indian Council of Medical Research (ICMR) 
and Department of Biotechnology (DBT) in 2007 [33]. This regulatory guidance 
formally prohibited the use of stem cells in human patients, except in the context of 
formally approved clinical trials [33]. In practice, however, this approach was not 
consistently implemented and India became one of the countries in which unproven or 
non-systematically tested stem cell interventions flourished on a large scale [5]. In 
order to address these problems, the Indian authorities issued a revised regulatory 
approach in 2013, laid down in the Guidelines for Stem Cell Research [34].   
These guidelines reconfirmed the prohibition of non-approved commercial 
applications with stem cells and stated that all clinical trials with stem cells had to be 
approved by The Drug Controller General India (DCGI). In 2014, the DCGI 
announced that stem cells were treated as a drug product and that clinical trials and 
pre-market approval had to conform to the Indian Drugs and Cosmetics Act, which 
included a new section on stem cells [35]. With these adjustments, the regulation of 
clinical stem cell research was formally put under statutory law. 
At the level of clinic practice, however, the situation remained diverse. Stem 
cell trials continue to be conducted outside of DCGI control and unapproved or non-
systematically proven stem cell interventions are still offered in many hospitals [36].  
As a result of this uneven implementation, the current regulatory situation in India can 
best be described as flexible, and as serving multiple interests and stakeholder groups 
simultaneously [3]. On the one hand, the DCGI’s requirement for multiphase trials 
and international best practice standards facilitates formal approval and marketization 
of stem cell-based medicinal products at a national and international level. This is 
exemplified by the DCGI’s approval of the first stem cell product in May 2016, which 
shall soon also be marketed in the EU, in the context of the EMA’s orphan 
designation scheme [37]. On the other hand, the lack of coherent regulatory 
enforcement and the continued toleration of unapproved clinical applications [35] 
enables physician-based forms of innovation and localized forms of profit making 
outside of the regulatory system.  
 
China 
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The development of a regulatory framework for clinical stem cell applications in 
China has been an ongoing process and much slower than for instance in the 
European Union or the USA. As in India, a large market of experimental for-profit 
interventions with stem cells emerged in the early 2000s. Following an initial attempt 
to control the provision of these unproven or non-systematically tested interventions 
in 2009, which failed [38], the Chinese health authorities introduced a regulatory 
white paper, in 2013, which formed the basis of a more comprehensive regulatory 
framework for clinical stem cell research that was publicized in August 2015 [39]. 
The 2015 Regulation for Clinical Stem Cell Research, jointly issued by the National 
Health and Family Planning Commission (NHFPC) and the Chinese Food and Drug 
Administration (CFDA), states that the clinical translation of stem cell-based 
approaches must occur through systematic clinical studies, which must follow from 
sound pre-clinical evidence. The core of this regulation is that stem cell trials can only 
be conducted in specifically authorized research hospitals and that for-profit 
applications of experimental stem cell interventions are legally prohibited. If this rule 
is implemented, this would mean the delimitation of clinical stem cell interventions to 
a small number of elite hospitals. It would also mean the systematic shutting down of 
numerous for-profit stem cell clinics [39]. While this evolving regulatory approach 
indicates an important step toward the improved review and governance of clinical 
stem cell research and applications in China, there are still numerous unresolved 
questions with this framework. A first set of questions concerns implementation: will 
the Chinese authorities have the political will to mobilize sufficient resources and 
administrative infrastructures to consistently implement this new regulatory model?  
Or will informal stem cell interventions continue to exist next to formally approved 
clinical trials and treatments, as in India and other countries? A second set of 
questions concerns the exact methodological requirements that will be required in pre-
market evaluations. In the 2015 guidelines, this point remained undefined. It is 
unclear whether stem cells shall be regulated as a pharmaceutical product or a medical 
technology, and also which types of clinical studies the NHFPC and CFDA require 
before approving routine clinical use. While the 2013 white paper mentioned phase 
I‒III trials, the 2015 regulation only speaks of clinical studies that shall be conducted 
according to “scientific principles” [39]. This could well mean that China’s health 
regulators leave this question deliberately open so as to have the flexibility to follow 
the current Japanese model rather than the more costly USA or EU model. 
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Argentina 
 
The clinical use of stem cells is currently regulated under the Ministerial Resolution 
No. 610/2007 from the Argentinean Ministry of Health. This resolution states that the 
use of human cells falls under the authority of the Unique Central Institute for 
Ablation and Implantation (INCUCAI). By falling under the authority of INCUCAI, 
stem cell interventions are not governed as a medical product (as in the EU, India and 
the USA) but as a medical procedure, which are managed by the Argentinean 
Transplant Act. With the exception of haematopoietic cell transplants from human 
bone marrow, all types of stem cells are considered experimental and require 
evaluation of safety and efficacy through clinical research [40, 41]. In the late 2000s, 
a dispute emerged among Argentina’s regulators whether stem cells should also be 
regulated as a medical product. In that case, Argentina’s National Administration of 
Drugs, Food and Medical Technology (ANMAT) would start to play a major role in 
regulation. A first step into this direction was achieved in 2011 by ANMAT 
regulation 7075/2011, in which more than minimally modified cellular products were 
classified as Advanced Therapeutic Medicinal Products (ATMP). At present, 
however, ANMAT has no legal authority to enforce approval of stem cells treatments 
under its rule, and it has not been decided in which situation researchers should apply 
at ANMAT or INCUCAI. Because INCUCAI’s regulation does not discriminate 
between different cell types, specific procedures of cell manipulation, or different 
levels of risks, the regulation could be considered so broadly as to include even 
human embryonic stem cells [40]. However, a new regulatory approach that will 
provide clarity on these issues is currently being drafted by the Ministry of Health 
(MOH), together with Argentina’s Advisory Committee on Stem Cells and 
Regenerative Medicine [42].  
In practice, the legal reach of both INCUCAI and ANMAT is limited. 
Argentina is a federal country in which national regulatory authorities have legal 
power only when medical products cross provincial borders or are involved in foreign 
trade. As a result, federal regulations are not applicable at the provincial level as long 
as medical treatments or services are applied exclusively within the geographic 
jurisdiction of a province [40]. A situation exists where there is no effective control 
over stem cell-based clinical applications if these interventions are not offered or 
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shipped across multiple provinces. According to estimates of policy experts and 
representatives of patient associations, this undefined regulatory grey area has 
resulted in the increase of experimental for-profit interventions with stem cells, which 
have been provided by at least ten private clinics in the country [43]. 
 
Brazil 
 
The development of a regulatory framework for clinical stem cell research in Brazil 
has been challenging for two reasons: religious opposition to stem cell research, and a 
constitutional prohibition that bans the commercial use of human cells and tissues 
[44]. Religious protests first flared up in 2005, when the Brazilian Congress approved 
Law #11,105, which legitimized the use of human embryonic stem cells (hESC) for 
research, including in clinical trials. According to this law, the regulation for the 
production and clinical use of hESC and other types of stem cells (with the exception 
of bone marrow transplants) fell under the responsibility of Brazil’s National Agency 
for Health Surveillance (ANVISA), the country’s national drug regulatory authority 
[44]. Yet, following a complaint by the Catholic Church at the Brazilian Supreme 
Court, the authorization of the use of embryos for research purposes was suspended 
for three years. In 2008, a final verdict confirmed that the 2005 law was valid, and 
that hESC research could go ahead [45]. According to officials of ANVISA this three-
year deliberation delayed the development of effective regulation also for other types 
of stem cells [44]. A first regulatory step for the clinical use of stem cells was issued 
by ANVISA in March 2011, in the form of ANVISA Board Resolution #9. However, 
this regulation specified solely the technical standards for the harvesting, derivation, 
processing, storage and quality controls for clinical use of stem cells. It did not 
address standards for clinical trials and market authorization. The reason for this was 
that the Brazilian constitution prohibits the commercialization of human body 
materials, including human cells and their derivates [44]. As a result, market approval 
and commercial distribution have until to this moment not been permitted. Regulatory 
debates on this issue within ANVISA and the Brazilian MOH are ongoing. However, 
because ANVISA has since 2013 worked on a draft regulation for clinical trials for 
advanced cell products, it is expected that commercialization of stem cell products 
will ultimately be approved in Brazil [44]. One consequence of this constitutional 
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prohibition is that the number of for-profit providers of experimental stem cell 
interventions has been much lower than in other countries [5].  
 
Regulatory diversification: implications for regulatory harmonization 
 
What can currently be observed in the regulatory landscape of stem cell research is a 
conflict between two central dynamics: the striving for international harmonization, 
on the one hand, and an increasing process of regulatory diversification, on the other. 
Attempts of regulatory harmonization are exemplified by the US FDA-EMA-Health 
Canada Advanced Therapy Medicinal Products (ATMP) Cluster, which since 2008 
has focused on the convergence of regulatory protocols for cellular therapies between 
regulatory authorities in the USA, the EU and Canada [46]. Another example is the 
Cell Therapy Working Group of the International Pharmaceutical Regulators Forum 
(IPRF; founded in 2011), which aims to establish best regulatory practices and to 
realize gradual regulatory harmonization in the cellular medicine field [47]. Like the 
US FDA-EMA-Health Canada ATMP Cluster, the IPRF Cell Therapy Working 
Group comprises primarily regulatory authorities from high-income countries, namely 
the USA, the EU, Canada, Australia, New Zealand, Singapore, Taiwan and South 
Korea [48].  
On the other hand, and in contrast to these ongoing attempts of regulatory 
harmonization, we are witnessing an increasing dynamics of regulatory 
diversification. As this paper has shown, this shift toward diversification is 
exemplified by three central processes. First is the emergence of a growing number of 
regulatory exceptions and exemptions that were initiated by drug regulatory 
authorities in high-income countries. These exceptions/exemptions facilitate 
processes of clinical translation, and sometimes commercial clinical applications [24], 
outside of the multiphase trial system, but within the confines and review procedures 
of national regulatory agencies. Salter, Zhou and Datta have described this process as 
a form of “hegemonic adjustment”, through which national governments have altered 
regulatory frameworks and clinical methodologies to enable greater responsiveness to 
health consumer needs [24].  
A second process of diversification is flexible enforcement of regulatory rules 
in some countries, in particular the toleration of clinical for-profit interventions with 
stem cells outside of the review and control structures of regulatory agencies. This has 
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happened for years in India and China [49], and in recent years increasingly also in 
the USA [47], where governments responded only gradually to a flourishing grey-area 
market of stem cell interventions [49, 50]. Unapproved for-profit applications 
continue to be tolerated in these countries also after the introduction of national 
regulatory frameworks, which formally prohibit these experimental interventions. 
This is the case in both China and India, where large private hospitals and medical 
corporations continue to offer their services on the Internet and seek to attract 
“medical tourists” from all over the world [5, 51, 52]. Sleeboom-Faulkner et al. have 
interpreted this “flexible” or “dual” regulatory approach as an attempt of national 
governments to serve the interests of domestic and international elite scientists and 
corporations on the one hand (by introducing regulatory frameworks that comply with 
EBM and international best-practice standards), and the interests of less well-funded 
local researchers and companies on the other hand (by tolerating grey-area clinical 
applications and business practices exterior to formal regulatory rules) [3, 49]. It is of 
interest that the toleration of unapproved stem cell interventions has not been 
restricted to middle-income countries, but could also be observed in the USA, where 
regulators took a surprisingly relaxed approach to many direct-to-consumer [DTC] 
stem cell clinics [50]. According to Turner and Knoepfler, there are currently more 
than 350 US businesses offering unapproved DTC interventions with stem cells. 
These businesses use both allogenic and autologous cells (including xenogeneic and 
self-proclaimed ‘induced pluripotent stem cells’ and ‘human embryonic stem cells’) 
for a variety of conditions ranging from ALS, Alzheimer’s and other 
neurodegenerative diseases, to cardiac diseases, pulmonary disorders, and also 
cosmetic applications. [50].  This development is partly driven by a growing number 
of rights-to-try laws in now more than twenty US states, and widespread calls for 
deregulation from various patient organizations [53]. However, as Turner and 
Knoepfler suggest, entrepreneurial physicians offering stem cell interventions may 
also have been emboldened by regulatory inactivity from the side of the FDA [50].     
A third process of regulatory diversification in the stem cell field is 
characterized by the complete abandoning of the multiphase trial EBM system, as has 
happened in Japan. This model, as Sipp has pointed out, dramatically relaxes the need 
to demonstrate the clinical utility of cellular products prior to marketing, and raises 
critical questions regarding the testing of treatment efficacy [30]. According to Sipp, 
with this new approach ‘Japan clearly hopes to compete and succeed in the race to 
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build a regenerative medicine industry by flattening a few hurdles’ [30]. It is not 
unlikely that other countries will follow the Japanese regulatory model, or at least 
create new types of regulatory exceptions in which (conditional) market approval of 
stem cell treatments can be granted without preceding phase I‒III trials. However, as 
the case of Brazil illustrates, processes of regulatory heterogeneity are not exclusively 
driven by economic considerations or global competition. In Brazil, divergence from 
US and EU regulatory models has been caused by religious concerns and a 
constitutional prohibition to marketize human cell and tissue products. While this 
situation has not prevented the use of RCT methodology, it has precluded corporate-
sponsored trials and participation of Brazilian hospitals and companies in 
multicountry licensing procedures.   
Taken together, the absence of globally shared international regulatory 
standards for stem cell medicine, and the high level of regulatory diversification that 
is resulting from differences in national policies as well as ambiguities that stem from 
emerging or unclear regulatory arrangements, has created crucial challenges for 
international clinical trial collaborations and cross-country marketing procedures.  
 
Challenges for multicountry stem cell trials 
 
We will now highlight four challenges that result from the above-mentioned situation 
of regulatory diversification. The first problem is that regulatory variation necessitates 
ongoing in-depth research into the (changing) regulatory conditions of drug 
regulatory authorities in several countries. For corporate sponsors and clinical 
investigators, the diversified and rapidly changing regulatory situation in the stem cell 
field is often perplexing and gives rise to important organizational problems [54]. 
What is required is a comparative, long-term engagement with the review and 
approval criteria of the regulatory agencies in all countries in which a clinical study 
shall be executed. Differences between regulatory rules in these countries must be 
singled out at an early stage, so as to design clinical trial protocols that conform to 
multi-jurisdictional frameworks. This is a time consuming process that is complicated 
further by language barriers, cultural differences and differences in the ways in which 
regulatory requirements are enforced [55]. It is complicated further because different 
types of cells and stem cells are often regulated by different government agencies and 
different regulatory requirements and rules [56].  
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A second problem is that the need to interact with multiple regulatory 
authorities creates a high degree of organizational complexity [54, 57]. To apply for 
trials and market approval in multiple countries requires time, money, specialist staff, 
and a substantial administrative infrastructure. This is of course a general problem for 
clinical trials, not only for stem cell trials. However, because most stem cell trials are 
sponsored by academic investigators and small-to-mid size biotech companies, who 
have typically very limited resources, it is often difficult to meet the organizational 
requirements of multi-country trials, and even more so for researchers and 
corporations in low or middle-income countries [58]. 
A third challenge is that evolving or insufficiently defined regulatory 
procedures can impose significant delays, unexpected costs and uncertainties 
regarding the planning and conduct of clinical trials [54]. In countries where formal 
jurisdictional frameworks for cell and stem cell-based clinical interventions are not 
yet in place or are in an early development phase, the situation can be even more 
challenging. Drug regulatory authorities may either postpone or completely reject 
incoming investigational new drug (IND) applications. Emerging or unclear 
regulatory procedures for the development of stem cell treatments may cause severe 
problems to international clinical research partnerships. Unresolved regulatory 
conditions can result in yearlong delays, increase costs, and give rise to the need to 
relocate a trial to another country or region, necessitating yet more regulatory 
applications. 
A final problem is that regulatory differences between jurisdictions require 
extensive forms of self-governance, capacity building, training of clinical trial staff 
and often far-reaching changes of locally evolved conditions and practices in 
participating trial sites [54, 59]. The reason for this is that regulatory variation 
between countries has a direct impact on the research practices, clinical 
methodologies and for-profit strategies that are employed in local hospitals and 
research institutes. These differences (at the level of local institutions and practices) 
have to be identified and addressed, so as to warrant standardized implementation of 
clinical trial protocols and acceptance of clinical data by multiple regulatory agencies. 
In some countries, knowledge and experience on the conduct of multiphase RCTs is 
also limited among clinical researchers [60]. These discrepancies between countries, 
hospitals (and often also within hospitals) endanger the scientific integrity of stem 
cell-based multi-country trials, and have to be tackled at an early stage of the clinical 
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translation process [61]. To mitigate this challenge, intensive training of staff and 
changes in local research practices are required, so that clinical protocols can be 
implemented in a standardized and trustworthy way [54]. Unless adequate finance for 
these forms of scientific self-governance, training and education is set aside, the 
conduct of international multicenter stem cell trials remains a risky undertaking.   
 
Concluding remarks 
 
With a rising number of stem cell-based strategies entering the clinical development 
phase, the demand for international stem cell trials is growing. This article has shown, 
however, that the high level of regulatory diversity in the stem cell field provides 
important obstacles to the organization of multicountry stem cell clinical trials. 
Emerging and unclear regulations in some countries, and the absence of 
internationally harmonized regulatory frameworks, confront investigators with 
unexpected costs, time delays, or even the need to relocate a trial to another country 
or region. These factors, especially increased or unexpected costs, are likely to reduce 
possibilities of researchers in low and middle-income countries to participate in the 
stem cell market, and they are also likely to increase the market price of successfully 
proven stem cell treatments. The high level of regulatory heterogeneity in the stem 
cell field gives rise to a high level of administrative complexity, and requires far-
reaching forms of scientific self-governance, training, and the creation of effective 
coordination and monitoring structures. These forms of self-governance and capacity 
building constitute a fundamental precondition to successfully navigate through a 
diverse and internationally non-harmonized regulatory environment. It is important to 
note, in this respect, that the implementation of standardized clinical research 
protocols is more difficult to achieve in the field of stem cell medicine, than in other – 
more established – areas of medicine research. The key reason for this – aside from 
the issue of regulatory heterogeneity ‒ is the lack of well-established international 
clinical research platforms. In oncology research, for instance, long-standing 
international clinical research infrastructures have evolved over the course of several 
decades. These transnational platforms have developed their own centralized 
institutions that are responsible for the coordination of all successive steps of the 
clinical translation process, including controls of processes of data collection, 
recording and analysis [62]. In the stem cell field, however, such infrastructures are 
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only gradually emerging. While international projects such as the China SCI Net 
(http://www.chinascinet.org) show that multicountry clinical research platforms are 
evolving, this article has illustrated that these processes are complicated by the 
absence of internationally harmonized regulatory frameworks. The existence of 
strongly diverging regulatory, institutional and clinical research cultures across 
countries and regions makes the performance of standardized multicountry trials a 
challenging and risky organizational enterprise. 
 
Future Perspectives 
 
The process of regulatory diversification in regenerative medicine research, which has 
been described in this article, is likely to continue and deepen. With a growing 
number of regulatory alternatives in the European Union [1] and the USA [11, 50], 
and the introduction of conditional, limited-term market approval of stem cell 
products after early-phase trials in Japan [30], the EBM paradigm of medical research 
(with the multi-phase trial system at its core) seems to gradually lose its hegemonic 
status [24]. It remains to be seen whether other countries will follow the Japanese 
regulatory model. However, the emergence of parallel (and potentially 
incommensurable) regulatory zones and networks [2, 3, 63], in which researchers and 
companies can choose between different regulatory options to bring stem cell-based 
treatments to the clinic and market is possible. Of interest is that regulatory 
heterogeneity in the stem cell field is not only emerging between countries (and in 
relation to global differentials of wealth, health care as well as scientific and 
regulatory resources [3]), but increasingly also within national jurisdictions in high-
income countries [1, 11, 50, 53]. In the light of the growing pressure from patient 
organizations, international scientific and economic competition and an increasing 
market of grey area stem cell interventions [5, 53, 63], the shift toward more rapid, 
flexible and less rigorous procedures of market approval is likely to continue in many 
countries, including in the USA and the European Union.  
With the increase of regulatory divergence at both national and international 
levels [2], various questions remain critical. What is the impact of the diversification 
of regulatory arrangements on the credibility of stem cell therapies, and how do actors 
determine which standards and products they can trust? Can the scientific and safety 
standards of medicine research that have evolved during the last few decades (and 
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which have prevented large numbers of patients worldwide from exposure to 
fraudulent medicines and intolerable risks) be maintained under the alternative 
regulatory pathways that are currently emerging? Considering the reputational, 
financial and health risks of less stringent regulation, the assumption that rapid market 
approval produces economic advantages, may well prove wrong. Moreover, the 
adoption of stem cell therapies into national health insurance that lack solid proof of 
efficacy, is likely to prevent access to other treatments and to take away resources for 
research and development that may be of greater value in the long run [30]. In the 
light of these challenges, societies and policy makers are now confronted with the 
difficult task to find ways and criteria to systematically evaluate methodological 
alternatives, and to halt them if they are likely to give rise to irresponsible forms of 
clinical validation, unreliable evidence or (in the most extreme case) the 
legitimization of for-profit scams. Whether and to what extent policy organs will do 
so, depends on the political prioritization of this problem, and on the will to mobilize 
the resources, expertise and administrative infrastructures that are required to perform 
this task. 
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Executive Summary 
 
• The regulatory conditions through which stem cell-based medicinal 
interventions are translated from the lab bench to the clinic and the market are 
undergoing a significant process of diversification. 
 
• This process has far-reaching consequences for international regulatory 
harmonization and the organization of multi-country clinical trial 
collaborations.  
 
Regulatory comparison 
 
• The article explores these issues by examining regulatory developments in 
seven jurisdictions: Argentina, Brazil, China, the European Union, India, 
Japan and the USA. 
 
Regulatory diversification: implications for regulatory harmonization 
 
• Regulatory diversification is exemplified by three central processes:  
o A growing number of regulatory exemptions in many countries, which 
allow for clinical applications outside of the hegemonic multi-phase 
trial system. 
o Lenient enforcement of regulatory rules in many countries, which have 
resulted in the widespread toleration of experimental for-profit 
practices outside of the approval and review mechanisms of drug 
regulatory authorities. 
o The development of entirely new regulatory models, which have 
abandoned the use of multi-phase trials as a critical passage point for 
market approval. 
• These developments make processes of multi-country market approval of stem 
cell-based therapies increasingly difficult. 
 
Challenges for clinical trial collaborations 
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• The absence of shared regulatory standards for stem cell medicine has created 
important challenges for international clinical trial collaborations. 
• These challenges range from increased costs, time delays, to a high level of 
administrative complexity and the need for extensive forms of scientific self-
governance, staff training and the requirement of effective coordination and 
monitoring structures (which are necessary to compensate for regulatory gaps 
between countries). 
• These problems are likely to prevent medical progress and make the conduct 
of standardized multicountry trials to a challenging and risky organizational 
enterprise. 
• They are also likely to delay patients’ access to clinically proven stem cell 
therapies in many countries.   
 
 
 
 
 
 
